Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/3/2025

Management of Polyneuropathy with NCV Abnormalities in Upper Extremities

Diagnostic Considerations

  • Polyneuropathy with upper extremity involvement typically presents with distal sensory loss, reduced reflexes, and sometimes distal muscle weakness, often in a stocking-and-glove distribution 1
  • Nerve conduction velocity (NCV) studies are essential for confirming the diagnosis and determining whether the neuropathy is primarily axonal or demyelinating 2
  • For patients with peripheral motor neuropathy, serial neurologic examinations are recommended over repeated electromyography/nerve conduction studies for monitoring disease activity 3, 4

Underlying Cause Identification

  • A thorough workup should include screening for common causes of polyneuropathy, such as metabolic disorders, inflammatory conditions, and malignancy-related and paraneoplastic syndromes 1
  • When polyneuropathy is associated with vasculitis like polyarteritis nodosa (PAN), combined nerve and muscle biopsy is recommended over nerve biopsy alone for diagnosis 5, 4

Pharmacological Management

  • First-line medications for neuropathic pain management include duloxetine and tricyclic antidepressants 1
  • Dosing considerations include starting with low doses and titrating based on efficacy and tolerability 1

Non-Pharmacological Approaches

  • Physical therapy interventions should focus on maintaining optimal postural alignment, encouraging even distribution of weight, and graded activity to increase the time that affected limbs are used within functional activities 6
  • Occupational therapy can help with task adaptation to promote normal movement patterns and strategies to engage in daily activities despite sensory and motor deficits 6

Management of Specific Etiologies

  • For inflammatory or immune-mediated polyneuropathies, glucocorticoids with non-GC immunosuppressive agents are recommended for active disease 5, 4
  • For non-severe cases of immune-mediated polyneuropathy, non-GC immunosuppressive agents with glucocorticoids are preferred over glucocorticoids alone 5, 4

Rehabilitation Strategies

  • Avoid techniques that may worsen symptoms, such as cocontraction or tensing of muscles, and postures that promote prolonged positioning of joints at end range 6
  • Helpful rehabilitation approaches include general relaxation techniques, use of gross rather than fine movements, and learning "slow" movement activities such as yoga or tai chi to regain movement control 6

Monitoring and Follow-up

  • Regular monitoring should include serial neurologic examinations to assess disease progression or improvement, assessment of medication efficacy and side effects, and evaluation of functional status and quality of life 3, 5, 1

Common Pitfalls and Caveats

  • Avoid prolonged use of splinting, which may increase attention and focus to the affected area, lead to muscle deconditioning, and increase accessory muscle use and compensatory movement strategies 6
  • For patients with remission of polyneuropathy associated with conditions like PAN, consider discontinuation of non-GC immunosuppressive agents after 18 months rather than continuing indefinitely 5, 4